Healthcare costs and burden of myasthenia gravis for patients and society: a systematic review

Background and objectives: New and costly therapies for myasthenia gravis (MG) have been approved during the last years, and many more are in the pipeline. Cost-benefit analyses are needed as part of defining start and stop criteria for such treatments. In this systematic review, we examine healthcare costs associated with MG: METHODS: A systematic literature search combined the word "myasthenia gravis" with "health resources", and "costs". 1374 records were identified initially, and 44 were included in the final review.